Michael Esquerré is the Vice President leading Immuno-Oncology activities at Evotec. He has spent the past 15-years working in Cancer Immunotherapy within the industry. With a team of 42 immunologists, he is deeply involved in supporting various drug discovery projects within the Immuno-Oncology space. Their work encompasses different therapeutic modalities, including small molecules, biologics (such as antibodies and immune cell engagers), oligonucleotide therapeutics, cancer vaccines, and the Evotec internal off-the-shelf iPSC-based cell therapy portfolio in Oncology: EVOcells Oncology. Their focus is on understanding and characterizing the impact of drugs on the immune system, using tailored assays with primary immune cells isolated from healthy donors, and validating their findings with patient samples in a translational approach. Michael finds Evotec a compelling place to work due to its growth opportunities, emphasis on innovation, and diverse business models that allow him to engage in both internal research projects and collaborations with Biotech and big Pharma companies. The unique collaboration with clinicians at the IUCT-Oncopole further enhances the impact of their work in the field of cancer research.